Navigation Links
CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
Date:1/15/2010

VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the treatment of infectious diseases, announced today the appointment of Todd S. Burkhart as Vice President of Manufacturing/Facilities and Commercial Operations for its manufacturing facility.  Mr. Burkhart has over 30 years of experience in the manufacture and process development of biologicals, medical devices and other Active Pharmaceutical Ingredients (APIs).  During his distinguished  career in the Pharmaceutical and Biopharmaceutical Industry and prior to joining CEL-SCI, Mr. Burkhart has been responsible for all aspects of GMP manufacturing and operations, including production, materials controls and facilities maintenance.  In addition he has extensive experience in the design of manufacturing facilities meeting FDA GMP requirements.  Mr. Burkhart has also been involved in the building and/or running a number of major pharmaceutical facilities at companies such as Cephalon, Human Genome Sciences and Univax Biologics.

Geert Kersten, Chief Executive Officer of CEL-SCI, said:  "We are pleased to have been able to attract to our team such an accomplished executive, with deep experience and expertise in all facets of the manufacturing process for biologics and other drugs. This hire represents another step CEL-SCI has taken in order to increase the likelihood of a successful outcome of its global pivotal Phase III study of Multikine® for the treatment of head and neck cancer."

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global pivotal Phase III clinical trial in advanced pr
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
2. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
5. CEL-SCI Expands H1N1 Flu Virus Work
6. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
7. CEL-SCI Posts New Corporate Presentation to Website
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  MEI Pharma, ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at the inaugural Cantor Fitzgerald Healthcare ... time from Le Parker Meridien in ... can be accessed at www.meipharma.com . A replay will ...
(Date:7/1/2015)... July 1, 2015 Lupin ... Total Number of MPP Sub-licensees to Fourteen Companies ... Pool (MPP) announced the rapid expansion of its network of ... 50 projects to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin ... a promising new HIV medicine the MPP licensed from ViiV ...
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
Breaking Medicine Technology:MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3AVACEN Medical Patent Issued 2
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will ... the Twin Cities on Saturday, August 1, at Spring Lake Park High School. , ... more than $1 million worth of goods and services including free food, health services, ...
(Date:7/1/2015)... ... 2015 , ... Scoliosis is a disorder in which the normally straight vertical line of the ... 3 percent of the population, or an estimated 6 to 9 million people. While it ... ages of 10 and 15. Most types of scoliosis are more common in girls than ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... compensation law has just published a top ten list they hope will guide ... Click here to read it now. , More than 450 ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only ... a national chief nursing officer recruitment for Capital Health in ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... Research ... Examination Kit (Peek) smartphone app to test eyesight was just as accurate as those ... School of Hygiene and Tropical Medicine is responsible for the development of the test, ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3
... with golf tournament on August 4th, 2008 , ... Woburn, MA (PRWEB) ... that it will partner with Ovations for the Cure to promote awareness ... with the Driving for a Cure Golf Tournament on August 4th, 2008 ...
... A Women,s Cancer Initiative in Partnership with the Entertainment Industry ... Foundation,s Women,s Cancer Research Fund, ... Industry Foundation (EIF) announced today that Academy,Award(R) winning actress Gwyneth ... Fifth Avenue,s 2008 KEY TO THE CURE,campaign. KEY TO THE ...
... Senior Living,Inc. (NYSE: SRZ ) today updated ... webcast to discuss the Company,s 2007 financial results,and ... call will now be held on Friday, August ... issue its 2007 financial results and second-quarter 2008,preliminary ...
... action is largely perceived as a legitimate means ... shown industrial action can adversely affect those involved. ... at Griffith University, has examined the psychological impact ... while on strike from 2004-2006. , She ...
... women treated for breast cancer did not know that their ... same whether they undergo mastectomy or breast conserving surgery. Minority ... important factor of their treatment decision, according to a study ... women were also less likely to know about relative survival ...
... Preliminary results from Milliman,s,2008 Group Health Insurance Survey ... official rate of inflation but are lower than,premium ... renewal,increases of 8.5% for Health Maintenance Organizations (HMOs) ... trend toward lower,increases since peaking at 16.1% in ...
Cached Medicine News:Health News:SBLI and Ovations for the Cure Team up to Raise Cancer Awareness 2Health News:Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenue's 2008 KEY TO THE CURE Campaign 2Health News:Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenue's 2008 KEY TO THE CURE Campaign 3Health News:Gwyneth Paltrow Announced as EIF Ambassador to Saks Fifth Avenue's 2008 KEY TO THE CURE Campaign 4Health News:Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data 2Health News:Psychological downside to strike action 2Health News:Minorities less likely to know about breast cancer treatment options 2Health News:Minorities less likely to know about breast cancer treatment options 3Health News:Milliman Survey Indicates Lower Health Insurance Rate Increases 2
... OmniMD Medical Billing system allows a ... accounting. It is integrated with the ... The system interfaces with electronic clearinghouses ... With a set of reports, it ...
... CPNG3 single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... CPNG3 reagent provides a long shelf ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: